|
1
|
Lee YS, Oh YM, Shim TS, Kim WS, An JS,
Choi CM and Jang SH: The clinical outcomes of photodynamic therapy
in early lung cancer patients. Tuberc Respir Dis. 71:266–270. 2011.
View Article : Google Scholar
|
|
2
|
Alberg AJ, Ford JG and Samet JM; American
College of Chest Physicians. Epidemiology of lung cancer: ACCP
evidence-based clinical practice guidelines (2nd edition). Chest.
132:29S–55S. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ministry for Health, Welfare and Family
Affairs. 2008 Annual Report of Cancer Statistics in Korea. Ministry
for Health, Welfare and Family Affairs; Seoul: 2010
|
|
5
|
Molina R, Filella X, Auge JM, et al: Tumor
markers (CEA, CA 125, CYFRA 21-1, SCC, and NSE) in patients with
non-small cell lung cancer as an aid in histological diagnosis, and
prognosis. Comparison with the main clinical and pathological
prognostic factors. Tumour Biol. 24:209–218. 2003. View Article : Google Scholar
|
|
6
|
American Cancer Society. Cancer Prevention
& Early Detection Facts & Figures, 2011. American Cancer
Society; Atlanta: 2011
|
|
7
|
Scott WJ, Howington J, Feigenberg S,
Movsas B and Pisters K; American College of Chest Physicians.
Treatment of non-small cell lung cancer stage I and stage II: ACCP
evidence-based clinical practice guidelines (2nd edition). Chest.
132:234S–242S. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hirsch FR, Merrick DT and Franklin WA:
Role of biomarkers for early detection of lung cancer and
chemoprevention. Eur Respir J. 19:1151–1158. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brambilla C, Fievet F, Jeanmart M, de
Fraipont F, Lantuejoul S, Frappat V, Ferretti G, Brichon PY and
Moro-Sibilot D: Early detection of lung cancer: role of biomarkers.
Eur Respir J Suppl. 39:36S–44S. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brower V: Biomarker studies abound for
early detection of lung cancer. J Natl Cancer Inst. 101:11–13.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peng G, Tisch U, Adams O, Hakim M, Shehada
N, Broza YY, Billan S, Abdah-Bortnyak R, Kuten A and Haick H:
Diagnosing lung cancer in exhaled breath using gold nanoparticles.
Nat Nanotechnol. 4:669–673. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van Klaveren RJ, Oudkerk M, Prokop M, et
al: Management of lung nodules detected by volume CT scanning. N
Engl J Med. 361:2221–2229. 2009.
|
|
13
|
Yau G, Lock M and Rodrigues G: Systematic
review of baseline low-dose CT lung cancer screening. Lung Cancer.
58:161–170. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ilie M, Mazure NM, Hofman V, Ammadi RE,
Ortholan C, Bonnetaud C, Havet K, Venissac N, Mograbi B, Mouroux J,
Pouysségur J and Hofman P: High levels of carbonic anhydrase IX in
tumour tissue and plasma are biomarkers of poor prognostic in
patients with non-small cell lung cancer. Br J Cancer.
102:1627–1635. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yee J, Sadar MD, Sin DD, Kuzyk M, Xing L,
Kondra J, McWilliams A, Man SF and Lam S: Connective
tissue-activating peptide III: a novel blood biomarker for early
lung cancer detection. J Clin Oncol. 27:2787–2792. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Patz EF, Campa MJ, Gottlin EB, Kusmartseva
I, Guan XR and Herndon JE II: Panel of serum biomarkers for the
diagnosis of lung cancer. J Clin Oncol. 25:5578–5583. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Palmisano WA, Divine KK, Saccomanno G,
Gilliland FD, Baylin SB, Herman JG and Belinsky SA: Predicting lung
cancer by detecting aberrant promoter methylation in sputum. Cancer
Res. 60:5954–5958. 2000.PubMed/NCBI
|
|
18
|
Belinsky SA, Klinge DM, Dekker JD, Smith
MW, Bocklage TJ, Gilliland FD, Crowell RE, Karp DD, Stidley CA and
Picchi MA: Gene promoter methylation in plasma and sputum increases
with lung cancer risk. Clin Cancer Res. 11:6505–6511. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gray RD, Duncan A, Noble D, Imrie M,
O’Reilly DS, Innes JA, Porteous DJ, Greening AP and Boyd AC: Sputum
trace metals are biomarkers of inflammatory and suppurative lung
disease. Chest. 137:635–641. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kennedy TC, Miller Y and Prindiville S:
Screening for lung cancer revisited and the role of sputum cytology
and fluorescence bronchoscopy in a high-risk group. Chest.
117:72S–79S. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hirsch J, Hansen KC, Burlingame AL and
Matthay MA: Proteomics: current techniques and potential
applications to lung disease. Am J Physiol Lung Cell Mol Physiol.
287:L1–L23. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sung HJ and Cho JY: Biomarkers for the
lung cancer diagnosis and their advances in proteomics. BMB Rep.
41:615–625. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Potti A, Mukherjee S, Petersen R, et al: A
genomic strategy to refine prognosis in early-stage non-small-cell
lung cancer. N Engl J Med. 355:570–580. 2006. View Article : Google Scholar
|
|
24
|
Pleasance ED, Stephens PJ, O’Meara S, et
al: A small-cell lung cancer genome with complex signatures of
tobacco exposure. Nature. 463:184–190. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mitsudomi T and Yatabe Y: Mutations of the
epidermal growth factor receptor gene and related genes as
determinants of epidermal growth factor receptor tyrosine kinase
inhibitors sensitivity in lung cancer. Cancer Sci. 98:1817–1824.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
McDermott U, Downing JR and Stratton MR:
Genomics and the continuum of cancer care. N Engl J Med.
364:340–350. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Verma M and Manne U: Genetic and
epigenetic biomarkers in cancer diagnosis and identifying high risk
populations. Crit Rev Oncol Hematol. 60:9–18. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Habis AH, Vernon SD, Lee DR, Verma M and
Unger U: Molecular quality of exfoliated cervical cells:
implications for molecular epidemiology and biomarker discovery.
Cancer Epidemiol Biomarkers Prev. 13:492–496. 2004.PubMed/NCBI
|
|
29
|
Martin KJ, Fournier MV, Reddy GP and
Pardee AB: A need for basic research on fluid-based early detection
biomarkers. Cancer Res. 70:5203–5206. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Baylin SB: DNA methylation and gene
silencing in cancer. Nat Clin Pract Oncol. 2(Suppl 1): S4–S11.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Belinsky SA: Gene-promoter
hypermethylation as a biomarker in lung cancer. Nat Rev Cancer.
4:707–717. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Parker CE, Pearson TW, Anderson NL and
Borchers CH: Mass-spectrometry-based clinical proteomics–a review
and prospective. Analyst. 135:1830–1838. 2010.
|
|
33
|
Qian B, Zhang H, Zhang L, Zhou X, Yu H and
Chen K: Association of genetic polymorphisms in DNA repair pathway
genes with non-small cell lung cancer risk. Lung Cancer.
73:138–146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chatterjee SK and Zetter BR: Cancer
biomarkers: knowing the present and predicting the future. Future
Oncol. 1:37–50. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Verma M: Human epigenome and cancer. Human
Genome Epidemiology. Khoury M, Bedrosian SR, Gwinn M, Higgins JPT,
Ioannidis JPA and Little J: 2nd edition. Oxford University Press;
London: pp. 551–558. 2009, View Article : Google Scholar
|
|
36
|
Sidransky D: Emerging molecular markers of
cancer. Nat Rev Cancer. 2:210–219. 2002. View Article : Google Scholar
|
|
37
|
Zabarovsky ER, Lerman MI and Minna JD:
Tumor suppressor genes on chromosome 3p involved in the
pathogenesis of lung and other cancers. Oncogene. 21:6915–6935.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xue X, Zhu YM and Woll PJ: Circulating DNA
and lung cancer. Ann NY Acad Sci. 1075:154–164. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mao L, Lee JS, Kurie JM, et al: Clonal
genetic alterations in the lungs of current and former smokers. J
Natl Cancer Inst. 89:857–862. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wistuba II, Behrens C, Milchgrub S, Bryant
D, Hung J, Minna JD and Gazdar AF: Sequential molecular
abnormalities are involved in the multistage development of
squamous cell lung carcinoma. Oncogene. 18:643–650. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Verma M and Srivastava S: Epigenetics in
cancer: implications for early detection and prevention. Lancet
Oncol. 3:755–763. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Verma M and Kumar D: Application of
mitochondrial genome information in cancer epidemiology. Clin Chim
Acta. 383:41–50. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Enokida H, Shiina H, Igawa M, et al: CpG
hypermethylation of MDR1 gene contributes to the pathogenesis and
progression of human prostate cancer. Cancer Res. 64:5956–5962.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kaneuchi M, Sasaki M, Tanaka Y, Shiina H,
Verma M, Ebina Y, Nomura E, Yamamoto R, Sakuragi N and Dahiya R:
Expression and methylation status of 14-3-3 sigma gene can
characterize the different histological features of ovarian cancer.
Biochem Biophys Res Commun. 316:1156–1162. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Velculescu VE, Zhang L, Vogelstein B and
Kinzler KW: Serial analysis of gene expression. Science.
270:484–487. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Showe MK, Vachani A, Kossenkov AV, et al:
Gene expression profiles in peripheral blood mononuclear cells can
distinguish patients with non-small cell lung cancer from patients
with nonmalignant lung disease. Cancer Res. 69:9202–9210. 2009.
View Article : Google Scholar
|
|
47
|
McConkey DJ, Lee S, Choi W, Tran M,
Majewski T, Lee S, Siefker-Radtke A, Dinney C and Czerniak B:
Molecular genetics of bladder cancer: emerging mechanisms of tumor
initiation and progression. Urol Oncol. 28:429–440. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hennig G, Gehrmann M, Stropp U, Brauch H,
Fritz P, Eichelbaum M, Schwab M and Schroth W: Automated extraction
of DNA and RNA from a single formalin-fixed paraffin-embedded
tissue section for analysis of both single-nucleotide polymorphisms
and mRNA expression. Clin Chem. 56:1845–1853. 2010. View Article : Google Scholar
|
|
49
|
Hoffmann NE, Sheinin Y, Lohse CM, Parker
AS, Leibovich BC, Jiang Z and Kwon ED: External validation of IMP3
expression as an independent prognostic marker for metastatic
progression and death for patients with clear cell renal cell
carcinoma. Cancer. 112:1471–1479. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yanagihara N, Caplen N, Bowman E, et al:
Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Rosenfeld N, Aharonov R, Meiri E, et al:
MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol.
26:462–469. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang W, Winder T, Ning Y, et al: A let-7
microRNA-binding site polymorphism in 3′-untranslated region of
KRAS gene predicts response in wild-type KRAS patients with
metastatic colorectal cancer treated with cetuximab monotherapy.
Ann Oncol. 22:104–109. 2011.
|
|
53
|
Shenouda SK and Alahari SK: MicroRNA
function in cancer: oncogene or a tumor suppressor? Cancer
Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kulpa J, Wojcik E, Radkowski A,
Kolodziejski L and Stasik Z: CYFRA 21-1, TPA-M, TPS, SCC-Ag, and
CEA in patients with squamous cell lung cancer, and in chemical
industry workers as a reference group. Anticancer Res.
20:5035–5040. 2000.PubMed/NCBI
|
|
55
|
Lamy P, Grenier J, Kramar A and Pujol JL:
Pro-gastrin-releasing peptide, neuron specific enolase, and
chromogranin A as serum markers of small cell lung cancer. Lung
Cancer. 29:197–203. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Schneider J, Philipp M, Velcovsky HG, Morr
H and Katz N: Pro-gastrin-releasing peptide (ProGRP), neuron
specific enolase (NSE), carcinoembryonic antigen (CEA), and
cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer
in comparison to other lung diseases. Anticancer Res. 23:885–893.
2003.
|
|
57
|
Cho WC, Yip TT, Cheng WW and Au JS: Serum
amyloid A is elevated in the serum of lung cancer patients with
poor prognosis. Br J Cancer. 102:1731–1735. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Cremona M, Calabrò E, Randi G, De Bortoli
M, Mondellini P, Verri C, Sozzi G, Pierotti MA, La Vecchia C,
Pastorino U and Bongarzone I: Elevated levels of the acute-phase
serum amyloid are associated with heightened lung cancer risk.
Cancer. 116:1326–1335. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Abdullah M, Marwitz S, Kähler D, Schultz
H, Kugler C, Zabel P, Vollmer E and Goldmann T: Pulmonary
haptoglobin: a new marker for adenocarcinomas of the lung?
Pathology. 43:70–72. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Shah A, Singh H, Sachdev V, Lee J,
Yotsukura S, Salgia R and Bharti A: Differential serum level of
specific haptoglobin isoforms in small cell lung cancer. Curr
Proteomics. 7:49–65. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Coward JI, Nathavitharana R and Popat S:
True hypoglycaemia secondary to treatment with granulocyte colony
stimulating factor (G-CSF) in a diabetic patient with non-small
cell lung cancer. Lung Cancer. 75:133–135. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Song JS, Kim SY, Jo HJ, et al: The role
and significance of biomarker for plasma G-CSF in patients with
primary lung cancer. Tuber Respir Dis. 66:444–450. 2009. View Article : Google Scholar
|
|
63
|
Hanash SM, Pitteri SJ and Faca VM: Mining
the plasma proteome for cancer biomarkers. Nature. 452:571–579.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Taguchi A, Politi K, Pitteri SJ, et al:
Lung cancer signatures in plasma based on proteome profiling of
mouse tumor models. Cancer Cell. 20:289–299. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Jeong HC, Kim GI, Cho SH, Lee KH, Ko JJ,
Yang JH and Chung KH: Proteomic analysis of human small cell lung
cancer tissues: up-regulation of coactosin-like protein-1. J
Proteome Res. 10:269–276. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Du J, Yang S, Lin X, Bu L, Nan Y, Huo S
and Shang W: Use of anchorchip-time-of-flight spectrometry
technology to screen tumor biomarker proteins in serum for small
cell lung cancer. Diagn Pathol. 5:602010. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Rahman SM, Gonzalez AL, Li M, et al: Lung
cancer diagnosis from proteomic analysis of preinvasive lesions.
Cancer Res. 71:3009–3017. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Seydel C: Quantum dots get wet. Science.
300:80–81. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Guha U, Chaerkady R, Marimuthu A, et al:
Comparisons of tyrosine phosphorylated proteins in cells expressing
lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci
USA. 105:14112–14117. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Haura EB, Müller A, Breitwieser FP, Li J,
Grebien F, Colinge J and Bennett KL: Using iTRAQ combined with
tandem affinity purification to enhance low-abundance proteins
associated with somatically mutated EGFR core complexes in lung
cancer. J Proteome Res. 10:182–190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Zeng X, Hood BL, Sun M, Conrads TP, Day
RS, Weissfeld JL, Siegfried JM and Bigbee WL: Lung cancer serum
biomarker discovery using glycoprotein capture and liquid
chromatography mass spectrometry. J Proteome Res. 9:6440–6449.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Taniguchi K, Uchida J, Nishino K, Kumagai
T, Okuyama T, Okami J, Higashiyama M, Kodama K, Imamura F and Kato
K: Quantitative detection of EGFR mutations in circulating tumor
DNA derived from lung adenocarcinomas. Clin Cancer Res.
17:7808–7815. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Kaiser J: Medicine. Cancer’s circulation
problem. Science. 327:1072–1074. 2010.
|
|
74
|
Pantel K, Alix-Panabieres C and Riethdorf
S: Cancer micrometastases. Nat Rev Clin Oncol. 6:339–351. 2009.
View Article : Google Scholar : PubMed/NCBI
|
